Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Gatza, Catherine E., Jennifer L. Elderbroom, Sun Young Oh, Mark D. Starr, Andrew B. Nixon, and Gerard C. Blobe. “The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.” Neoplasia 16, no. 6 (June 2014): 489–500. https://doi.org/10.1016/j.neo.2014.05.008.

PMID
25077702
Full Text

Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.

Full Text

Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.

Full Text

Hatch, Ace Joseph, Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Chen Jiang, Alexander Sibley, et al. “Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, 32:11022–11022. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11022.

Full Text

Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.

PMID
24173967
Full Text

Secord, Angeles Alvarez, Deanna Teoh, Jingquan Jia, Andrew B. Nixon, Lisa Grace, David J. Adams, and Susan K. Murphy. “Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.” Int J Gynecol Cancer 24, no. 2 (February 2014): 218–25. https://doi.org/10.1097/IGC.0000000000000056.

PMID
24407585
Full Text

Hatch, Ace J., Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Donna Niedzwiecki, Alan Paul Venook, Stephanie M. Cushman, Herbert Hurwitz, and Andrew B. Nixon. “Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, 32:448–448. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.3_suppl.448.

Full Text

Kumar, S., C. C. Pan, J. C. Bloodworth, A. B. Nixon, C. Theuer, D. G. Hoyt, and N. Y. Lee. “Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.” Oncogene 33, no. 30 (2014): 3970–79. https://doi.org/10.1038/onc.2013.386.

Full Text

Lopez-Acevedo, Micael, Lisa Grace, Deanna Teoh, Regina Whitaker, David J. Adams, Jingquan Jia, Andrew B. Nixon, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.” Gynecol Oncol Res Pract 1 (2014): 2. https://doi.org/10.1186/2053-6844-1-2.

PMID
27231555
Full Text

Dellinger, Andrew E., Andrew B. Nixon, and Herbert Pang. “Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.” Cancer Inform 13, no. Suppl 4 (2014): 1–9. https://doi.org/10.4137/CIN.S13634.

PMID
25125969
Full Text

Pages